Announcement PDF Resonance Health Ltd Web www.resonancehealth.com General inquiries info@resonancehealth.com T + 61 8 9286 5300 F +61 8 9286 5399 Head Office 141 Burswood Road, Burswood, WA, 6100, AUSTRALIA Postal address PO Box 108, Victoria Park, WA, 6979, AUSTRALIA 20 October 2026 Dear Shareholder 2026 Annual General Meeting - Notice of Meeting & Explanatory Statement, and Proxy Form Resonance Health Limited (ASX: RHT) (Company or Resonance Health) is holding its 2026 Annual General Meeting (AGM) on Thursday, 19 November 2026 at 10:00 am (AWST) at the following location: Conference Centre QV1 Building – Level 2 250 St Georges Terrace Perth, Western Australia, 6000. The Company will not dispatch physical copies of the Notice of Meeting & Explanatory Statement (Notice) to shareholders who have not previously opted in to receiving electronic copies. The Notice is available at, and can be downloaded at, the following link: https://www.resonancehealth.com/investor/asx/ How to Vote Resonance Health shareholders may vote at the AGM by attending the AGM in person, or by proxy, or by appointing an authorised representative. Voting in Person To vote in person, please attend the AGM on the date and at the place noted above. Shareholders are asked to arrive 15 minutes prior to the time designated for the AGM, so that the Company may check each shareholder’s holding against the Company’s share register and note attendance. Voting by Proxy Appointment of Proxy: Shareholders who are entitled to attend and vote at the AGM, may appoint a proxy to act generally at the AGM and vote on their behalf. The proxy does not need to be a Resonance Health shareholder. A shareholder who is entitled to cast two or more votes may appoint two proxies and should specify the proportion of votes each proxy is entitled to exercise. If a shareholder appoints two proxies but does not specify the proportion or number of votes to be cast by those proxies, each proxy may exercise half of the shareholder's votes. Resonance Health Ltd Web www.resonancehealth.com General inquiries info@resonancehealth.com T + 61 8 9286 5300 F +61 8 9286 5399 Head Office 141 Burswood Road, Burswood, WA, 6100, AUSTRALIA Postal address PO Box 108, Victoria Park, WA, 6979, AUSTRALIA Voting by proxy: A shareholder can direct their proxy to vote for, against, or abstain from voting on each Resolution by marking the appropriate box in the voting directions on the proxy section of the enclosed Proxy Form. If a proxy holder votes, they must cast all votes as directed. Any directed proxies that are not voted will automatically default to the Chair of the AGM, who must vote the proxies as directed in the Proxy Form. Proxy Forms must be received by 10:00 am (AWST) on Tuesday, 17 November 2026. Details on how to lodge your Proxy Form can be found in the enclosed Proxy Form. If you have any questions about your Proxy Form, please contact the Company Secretary by telephone at +61 8 9286 5300 or by email at: mitchellw@resonancehealth.com The Notice is important and should be read in its entirety. If you are in doubt as to the course of action you should follow, please consult your financial adviser, lawyer, accountant, or other professional adviser. Yours faithfully Mitchell Wells Non-executive Director & Company Secretary Resonance Health Ltd 1 RESONANCE HEALTH LIMITED ACN 006 762 492 NOTICE OF ANNUAL GENERAL MEETING Notice is given that the Meeting will be held at: TIME: 10:00am (AWST) DATE: Thursday, 19 November 2026 PLACE: QV1 Conference Centre Level 2, 250 St Georges Terrace PERTH WA 6000 The business of the Meeting affects your shareholding and your vote is important. This Notice should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their professional advisers prior to voting. The Directors have determined pursuant to Regulation 7.11.37 of the Corporations Regulations 2001 (Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders at 4:00pm (AWST) on Tuesday, 17 November 2026. B US I NE S S OF T HE ME E T I NG AGENDA FINANCIAL STATEMENTS AND REPORTS To receive and consider the annual financial report of the Company for the financial year ended 30 June 2026 together with the declaration of the Directors, the Directors’ report, the Remuneration Report and the auditor’s report. 1. RESOLUTION 1 – ADOPTION OF REMUNERATION REPORT To consider and, if thought fit, to pass, with or without amendment, the following resolution as a non-binding resolution: “That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, approval is given for the adoption of the Remuneration Report as contained in the Company’s annual financial report for the financial year ended 30 June 2026.” Note: the vote on this Resolution is advisory only and does not bind the Directors or the Company. 2. RESOLUTION 2 – ELECTION OF DIRECTOR – MR MICHAEL SISTENICH To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution: “That, for the purpose of clause 15.4 of the Constitution, Listing Rule 14.4 and for all other purposes, Mr Michael Sistenich, a Director who was appointed as an additional Director on 28 April 2026, retires, and being eligible, is elected as a Director.” 3. RESOLUTION 3 – ELECTION OF DIRECTOR – DR DAVID FULLER To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution: “That, for the purpose of clause 15.4 of the Constitution, Listing Rule 14.4 and for all other purposes, Dr David Fuller, a Director who was appointed as an additional Director on 28 April 2026, retires, and being eligible, is elected as a Director.” 4. RESOLUTION 4 – RE-ELECTION OF DIRECTOR – DR TRAVIS BARONI To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution: “That, for the purpose of clause 15.2 of the Constitution and for all other purposes, Dr Travis Baroni, a Director, retires by rotation, and being eligible, is re-elected as a Director.” 5. RESOLUTION 5 – APPROVAL OF 7.1A MANDATE To consider and, if thought fit, to pass the following resolution as a special resolution: “That, for the purposes of Listing Rule 7.1A and for all other purposes, approval is given for the Company to issue up to that number of Equity Securities equal to 10% of the issued capital of the Company at the time of issue, calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and otherwise on the terms and conditions set out in the Explanatory Statement.” 6. RESOLUTION 6 – APPROVAL TO ISSUE SECURITIES UNDER AN INCENTIVE PLAN To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution: “That, for the purposes of Listing Rule 7.2 (Exception 13(b)) and for all other purposes, approval is given for the Company to issue up to a maximum of 35,000,000 Securities under the employee incentive scheme titled ‘Incentive Awards Plan’, on the terms and conditions set out in the Explanatory Statement.” 7. RESOLUTION 7 – ISSUE OF LOAN SHARES TO DIRECTOR – MR ANDREW HARRISON To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution: “That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue up to 6,850,749 Loan Shares to Mr Andrew Harrison (or his nominee(s)) under the Incentive Awards Plan on the terms and conditions set out in the Explanatory Statement.” 8. RESOLUTION 8 – AMENDMENT TO CONSTITUTION To consider and, if thought fit, to pass the following resolution as a special resolution: “That, for the purposes of section 136(2) of the Corporations Act and for all other purposes, approval is given for the Company to amend clause 2.4 of the Constitution by replacing the reference to ‘5%’ with ‘15%’, setting the issue cap for issues of Securities under the Plan to 15% of the issued capital of the Company for the purposes of section 1100V(2) of the Corporations Act.” Dated: 14 October 2026 Voting Prohibition Statements Resolution 1 – Adoption of Remuneration Report In accordance with sections 250BD and 250R(4), a vote on this Resolution must not be cast: (a) by or on behalf of a member of the Key Management Personnel, details of whose remuneration are included in the Remuneration Report or a Closely Related Party of such a member, regardless of the capacity in which the vote is cast; or (b) as a proxy by a member of the Key Management Personnel at the date of the Meeting, or their Closely Related Parties. However, a person (the voter) described above may cast a vote on this Resolution as a proxy if the vote is not cast on behalf of a person described above and either: (a) the voter is appointed as a proxy by writing that specifies the way the proxy is to vote on this Resolution; or (b) the voter is the Chair and the appointment of the Chair as proxy: (i) does not specify the way the proxy is to vote on this Resolution; and (ii) expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with the remuneration of a member of the Key Management Personnel. Resolution 6 – Approval to Issue Securities under an Incentive Plan A person appointed as a proxy must not vote, on the basis of that appointment, on this Resolution if: (a) the proxy is either: (i) a member of the Key Management Personnel; or (ii) a Closely Related Party of such a member; and (b) the appointment does not specify the way the proxy is to vote on this Resolution. However, the above prohibition does not apply if: (c) the proxy is the Chair; and (d) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with remuneration of a member of the Key Management Personnel. Resolution 7 – Issue of Loan Shares to Director – Mr Andrew Harrison A person appointed as a proxy must not vote, on the basis of that appointment, on this Resolution if: (a) the proxy is either: (i) a member of the Key Management Personnel; or (ii) a Closely Related Party of such a member; and (b) the appointment does not specify the way the proxy is to vote on this Resolution. However, the above prohibition does not apply if: (c) the proxy is the Chair; and (d) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with remuneration of a member of the Key Management Personnel. Voting Exclusion Statements In accordance with Listing Rule 14.11, the Company will disregard any votes cast in favour of the Resolution set out below by or on behalf of the following persons: Resolution 5 – Approval of 7.1A Mandate A person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person (or those persons). Resolution 6 – Approval to Issue Securities under an Incentive Plan A person who is eligible to participate in the employee incentive scheme or an associate of that person or those persons. Resolution 7 – Issue of Loan Shares to Director – Mr Andrew Harrison Mr Andrew Harrison (or his nominee(s)) and any other person referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3 who is eligible to participate in the employee incentive scheme in question or an associate of that person or those persons. However, this does not apply to a vote cast in favour of the Resolution by: (a) a person as a proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the proxy or attorney to vote on the Resolution in that way; or (b) the Chair as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and (ii) the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way. Voting by proxy To vote by proxy, please complete and sign the enclosed Proxy Form and return by the time and in accordance with the instructions set out on the Proxy Form. In accordance with section 249L of the Corporations Act, Shareholders are advised that: • each Shareholder has a right to appoint a proxy; • the proxy need not be a Shareholder of the Company; and • a Shareholder who is entitled to cast two or more votes may appoint two proxies and may specify the proportion or number of votes each proxy is appointed to exercise. If the Shareholder appoints two proxies and the appointment does not specify the proportion or number of the member’s votes, then in accordance with section 249X(3) of the Corporations Act, each proxy may exercise one-half of the votes. Shareholders and their proxies should be aware that: • if proxy holders vote, they must cast all directed proxies as directed; and • any directed proxies which are not voted will automatically default to the Chair, who must vote the proxies as directed. Voting in person To vote in person, attend the Meeting at the time, date and place set out above. Should you wish to discuss the matters in this Notice please do not hesitate to contact the Company Secretary on + 61 8 9286 5300 or mitchellw@resonancehealth.com. 7 E XP L ANAT ORY S T AT E ME NT This Explanatory Statement has been prepared to provide information which the Directors believe to be material to Shareholders in deciding whether or not to pass the Resolutions. 1. FINANCIAL STATEMENTS AND REPORTS In accordance with the Corporations Act, the business of the Meeting will include receipt and consideration of the annual financial report of the Company for the financial year ended 30 June 2026 together with the declaration of the Directors, the Directors’ report, the Remuneration Report and the auditor’s report. The Company will not provide a hard copy of the Company’s annual financial report to Shareholders unless specifically requested to do so. The Company’s annual financial report is available on its website at http://www.resonancehealth.com/investor/. 2. RESOLUTION 1 – ADOPTION OF REMUNERATION REPORT 2.1 General The Corporations Act requires that at a listed company’s annual general meeting, a resolution that the remuneration report to be adopted must be put to the shareholders. However, such a resolution is advisory only and does not bind the company or the directors of the company. The remuneration report sets out the company’s remuneration arrangements for the directors and senior management of the company. The remuneration report is part of the directors’ report contained in the annual financial report of the company for a financial year. The chair of the meeting must allow a reasonable opportunity for its shareholders to ask questions about or make comments on the remuneration report at the annual general meeting. 2.2 Voting consequences A company is required to put to its shareholders a resolution proposing the calling of another meeting of shareholders to consider the appointment of directors of the company (Spill Resolution) if, at consecutive annual general meetings, at least 25% of the votes cast on a remuneration report resolution are voted against adoption of the remuneration report and at the first of those annual general meetings a Spill Resolution was not put to vote. If required, the Spill Resolution must be put to vote at the second of those annual general meetings. If more than 50% of votes cast are in favour of the Spill Resolution, the company must convene a shareholder meeting (Spill Meeting) within 90 days of the second annual general meeting. All of the directors of the company who were in office when the directors' report (as included in the company’s annual financial report for the most recent financial year) was approved, other than the managing director of the company, will cease to hold office immediately before the end of the Spill Meeting but may stand for re-election at the Spill Meeting. Following the Spill Meeting those persons whose election or re-election as directors of the company is approved will be the directors of the company. 2.3 Previous voting results At the Company’s previous annual general meeting the votes cast against the remuneration report considered at that annual general meeting were less than 25%. Accordingly, the Spill Resolution is not relevant for this Meeting. 8 3. RESOLUTION 2 – ELECTION OF DIRECTOR – MR MICHAEL SISTENICH 3.1 General Clause 15.4 of the Constitution allows the Directors to appoint at any time a person to be a Director either to fill a casual vacancy or as an addition to the existing Directors, but only where the total number of Directors does not at any time exceed the maximum number specified by the Constitution. Pursuant to the Constitution and Listing Rule 14.4, any Director so appointed holds office only until the next annual general meeting and is then eligible for election by Shareholders but shall not be taken into account in determining the Directors who are to retire by rotation (if any) at that meeting. Mr Michael Sistenich, having been appointed by other Directors on 28 April 2026 in accordance with the Constitution, will retire in accordance with the Constitution and Listing Rule 14.4 and being eligible, seeks election from Shareholders. Further information in relation to Mr Sistenich is set out below. Qualifications, experience and other material directorships Mr Sistenich is an experienced ASX listed company executive and Non-Executive Director with more than 25 years of global experience across healthcare, artificial intelligence, life sciences and institutional investing. Mr Sistenich is currently Chief Executive Officer and a Director of Enlitic, Inc. (ASX: ENL) (Enlitic), having previously served as its Non-Executive Chairman. At Enlitic, Mr Sistenich has led the company’s restructuring and recapitalisation and its initial public offering on ASX, and has overseen strategic acquisitions and global partnerships with healthcare and technology organisations. Mr Sistenich previously served as Chief Executive Officer and Non-Executive Director of Nohla Therapeutics, where he led the development and financing of a clinical-stage cellular therapy platform, and as a Non-Executive Director of Opthea Limited (ASX/Nasdaq: OPT). Mr Sistenich has extensive capital markets and investment banking experience, including as Director, Corporate Finance at Bell Potter Securities, where he led life sciences initial public offerings and capital raisings, and in senior investment roles at Lygon Capital Management, Meditor Capital Management and DWS Investments. He is a Founding Partner of Aurenda Partners, a corporate advisory firm focused on growth companies. Mr Sistenich holds a Master of Science (Biochemistry) from the University of Oxford and is a CFA Charterholder. Other than Enlitic, Mr Sistenich does not currently hold any other directorships in ASX listed companies. Term of office Mr Sistenich has served as a Director since 28 April 2026. Independence If elected, the Board considers that Mr Sistenich will be an independent Director. Other material information The Company conducts appropriate checks on the background and experience of candidates before their appointment to the Board. These include checks as to a person’s experience, educational qualifications, character, criminal record and bankruptcy history. The Company undertook such checks prior to the appointment of Mr Sistenich, which did not reveal any material information of concern. 9 Board recommendation Having received an acknowledgement from Mr Sistenich that he will have sufficient time to fulfil his responsibilities as a Director and having reviewed the performance of Mr Sistenich since his appointment to the Board and the skills, knowledge, experience and capabilities required by the Board, the Directors (other than Mr Sistenich) recommend that Shareholders vote in favour of this Resolution. 3.2 Technical information required by Listing Rule 14.1A If this Resolution is passed, Mr Sistenich will be elected to the Board as an independent Non-Executive Director. If this Resolution is not passed, Mr Sistenich will not continue in his role as an independent Non-Executive Director and will cease to be a Director at the conclusion of the Meeting. The Company may seek nominations or otherwise identify suitably qualified candidates to join the Company. As an additional consequence, this may detract from the Board and Company’s ability to execute on its strategic vision. 4. RESOLUTION 3 – ELECTION OF DIRECTOR – DR DAVID FULLER 4.1 General Clause 15.4 of the Constitution allows the Directors to appoint at any time a person to be a Director either to fill a casual vacancy or as an addition to the existing Directors, but only where the total number of Directors does not at any time exceed the maximum number specified by the Constitution. Pursuant to the Constitution and Listing Rule 14.4, any Director so appointed holds office only until the next annual general meeting and is then eligible for election by Shareholders but shall not be taken into account in determining the Directors who are to retire by rotation (if any) at that meeting. Dr David Fuller, having been appointed by other Directors on 28 April 2026 as an addition to the existing Directors in accordance with the Constitution, will retire in accordance with the Constitution and Listing Rule 14.4 and being eligible, seeks election from Shareholders. Further information in relation to Dr Fuller is set out below. Qualifications, experience and other material directorships Dr Fuller is a pharmaceutical physician and pharmacist with more than 30 years of international experience across drug development, clinical research, regulatory strategy and commercialisation. Dr Fuller is currently Chief Medical Officer of Dimerix Limited (ASX: DXB), where he leads clinical development, regulatory engagement and medical strategy for that company’s renal- focused therapeutic programs. Dr Fuller has experience across the full drug development lifecycle, including pre-clinical development, Phase I–III clinical trials, regulatory approvals, product launches and post- marketing activities, and has contributed to multiple regulatory submissions and approvals with major global agencies, including the US Food and Drug Administration and the European Medicines Agency. His prior executive experience includes Chief Medical Officer roles at Race Oncology (ASX: RAC), Aucentra Therapeutics and Arana Therapeutics, and senior leadership roles at Syneos Health, including as Senior VP, Clinical Development, where he was responsible for the growth and strategic direction of its oncology business unit across Asia-Pacific. Earlier in his career, Dr Fuller held senior roles at Genzyme and Orphan Medical, where he contributed to the clinical development, regulatory approval and launch of multiple therapies. 10 Dr Fuller has previously held director roles at Adalta Ltd, Epiaxis Therapeutics, Linear Clinical Research and Dimerix Bioscience. Dr Fuller holds a Bachelor of Medicine and Bachelor of Surgery and a Bachelor of Pharmacy (First Class Honours) from the University of Sydney, and is a registered medical practitioner in Australia and the United Kingdom. Dr Fuller does not currently hold any directorships in other ASX listed companies. Term of office Dr Fuller has served as a Director since 28 April 2026. Independence If elected, the Board considers that Dr Fuller will be an independent Director. Other material information The Company conducts appropriate checks on the background and experience of candidates before their appointment to the Board. These include checks as to a person’s experience, educational qualifications, character, criminal record and bankruptcy history. The Company undertook such checks prior to the appointment of Dr Fuller, which did not reveal any material information of concern. Board recommendation Having received an acknowledgement from Dr Fuller that he will have sufficient time to fulfil his responsibilities as a Director and having reviewed the performance of Dr Fuller since his appointment to the Board and the skills, knowledge, experience and capabilities required by the Board, the Directors (other than Dr Fuller) recommend that Shareholders vote in favour of this Resolution. 4.2 Technical information required by Listing Rule 14.1A If this Resolution is passed, Dr Fuller will be elected to the Board as an independent Non- Executive Director. If this Resolution is not passed, Dr Fuller will not continue in his role as an independent Non- Executive Director and will cease to be a Director at the conclusion of the Meeting. The Company may seek nominations or otherwise identify suitably qualified candidates to join the Company. As an additional consequence, this may detract from the Board and Company’s ability to execute on its strategic vision. 5. RESOLUTION 4 – RE-ELECTION OF DIRECTOR – DR TRAVIS BARONI 5.1 General The Constitution sets out the requirements for determining which Directors are to retire by rotation at an annual general meeting. Dr Travis Baroni, who has held office without re-election since 28 November 2024 and being eligible retires by rotation and seeks re-election. Further information in relation to Dr Baroni is set out below. Qualifications, experience and other material directorships Dr Baroni has broad experience across industrial research, commercialisation of technology, asset valuations and investment banking services. He has a bachelor’s degree and PhD in applied physics from The University of Western Australia and managed innovation development and technology strategy in a large company setting as well as being an active investor in early stage investments. He has worked in investment banking, providing advisory services to equity capital market transactions, corporate research and valuations to clients. Dr Baroni is Chair of the Audit & Risk Committee and a member of the Remuneration Committee. 11 Dr Baroni does not currently hold any other directorships in ASX listed companies. Term of office Dr Baroni has served as a Director since 25 November 2016 and was last re-elected on 28 November 2024. Independence If re-elected, the Board considers that Dr Baroni will be an independent Director. Board recommendation Having received an acknowledgement from Dr Baroni that he will have sufficient time to fulfil his responsibilities as a Director and having reviewed the performance of Dr Baroni since his appointment to the Board and the skills, knowledge, experience and capabilities required by the Board, the Directors (other than Dr Baroni) recommend that Shareholders vote in favour of this Resolution. 5.2 Technical information required by Listing Rule 14.1A If this Resolution is passed, Dr Baroni will be re-elected to the Board as an independent Non-Executive Director. If this Resolution is not passed, Dr Baroni will not continue in his role as an independent Non- Executive Director and will cease to be a Director at the conclusion of the Meeting. The Company may seek nominations or otherwise identify suitably qualified candidates to join the Company. As an additional consequence, this may detract from the Board and Company’s ability to execute on its strategic vision. 6. RESOLUTION 5 – APPROVAL OF 7.1A MANDATE 6.1 General This Resolution seeks Shareholder approval by way of special resolution for the Company to have the additional 10% placement capacity provided for in Listing Rule 7.1A to issue Equity Securities without Shareholder approval. Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of equity securities that a listed company can issue without the approval of its shareholders over any 12-month period to 15% of the fully paid ordinary shares it had on issue at the start of that period. Under Listing Rule 7.1A, an Eligible Entity may seek shareholder approval by way of a special resolution passed at its annual general meeting to increase this 15% limit by an extra 10% to 25% (7.1A Mandate). An Eligible Entity means an entity which is not included in the S&P/ASX 300 Index and has a market capitalisation of $300,000,000 or less. As of the date of this Notice, the Company’s market capitalisation is $39.60 million. The Company is therefore an Eligible Entity. 6.2 Technical information required by Listing Rule 14.1A For this Resolution to be passed, at least 75% of votes cast by Shareholders present and eligible to vote at the Meeting must be cast in favour of the Resolution. If this Resolution is passed, the Company will be able to issue Equity Securities up to the combined 25% limit in Listing Rules 7.1 and 7.1A without any further Shareholder approval. If this Resolution is not passed, the Company will not be able to access the additional 10% capacity to issue Equity Securities without Shareholder approval under Listing Rule 7.1A and will remain subject to the 15% limit on issuing Equity Securities without Shareholder approval set out in Listing Rule 7.1. 6.3 Technical information required by Listing Rule 7.3A REQUIRED INFORMATION DETAILS Period for which the 7.1A Mandate is valid The 7.1A Mandate will commence on the date of the Meeting and expire on the first to occur of the following: 12 REQUIRED INFORMA